FDA Seeks Speedier Seizure, Injunction Decisions Via Protocol Changes
This article was originally published in The Rose Sheet
Executive Summary
FDA is working to expedite its decision-making process for seizures and injunctions, which could translate into quicker enforcement actions for violative products.
You may also be interested in...
FDA's New ORA Head, Dara Corrigan, Has Broad Enforcement Experience
Former acting HHS inspector general will become associate commissioner for regulatory affairs two years after Margaret O'Keeffe Glavin's retirement.
Hamburg Offers "Close Out" Carrot To Firms In Plan To Accelerate Enforcement
FDA enforcement initiative eliminates requirement for all warning letters to be reviewed by Office of Chief Counsel.
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.